IQI Stock Overview
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Incannex Healthcare Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.07 |
52 Week High | US$0.56 |
52 Week Low | US$0.06 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | -56.25% |
1 Year Change | -80.34% |
3 Year Change | -80.98% |
5 Year Change | 250.00% |
Change since IPO | -68.75% |
Recent News & Updates
Recent updates
Shareholder Returns
IQI | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | 1.9% | 1.2% |
1Y | -80.3% | -28.2% | 2.0% |
Return vs Industry: IQI underperformed the German Pharmaceuticals industry which returned -25.2% over the past year.
Return vs Market: IQI underperformed the German Market which returned 9.2% over the past year.
Price Volatility
IQI volatility | |
---|---|
IQI Average Weekly Movement | 22.9% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IQI's share price has been volatile over the past 3 months.
Volatility Over Time: IQI's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | Joel Latham | www.incannex.com |
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.
Incannex Healthcare Inc. Fundamentals Summary
IQI fundamental statistics | |
---|---|
Market cap | €1.50b |
Earnings (TTM) | -€12.30m |
Revenue (TTM) | €624.42k |
2,631x
P/S Ratio-133.5x
P/E RatioIs IQI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IQI income statement (TTM) | |
---|---|
Revenue | AU$1.01m |
Cost of Revenue | AU$0 |
Gross Profit | AU$1.01m |
Other Expenses | AU$20.99m |
Earnings | -AU$19.98m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.05 |
Gross Margin | 100.00% |
Net Profit Margin | -1,970.61% |
Debt/Equity Ratio | 0% |
How did IQI perform over the long term?
See historical performance and comparison